OKYO Pharma Ownership
| OKYO Stock | USD 1.04 0.01 0.95% |
Shares in Circulation | First Issued 2008-03-31 | Previous Quarter 15.1 M | Current Value 22.9 K | Avarage Shares Outstanding 28.3 M | Quarterly Volatility 178 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
OKYO |
OKYO Stock Ownership Analysis
About 28.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.57. OKYO Pharma had not issued any dividends in recent years. OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom. Okyo Pharma is traded on NASDAQ Exchange in the United States. To find out more about OKYO Pharma Ltd contact Gary Jacob at 44 20 7495 2379 or learn more at https://okyopharma.com.Besides selling stocks to institutional investors, OKYO Pharma also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different OKYO Pharma's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align OKYO Pharma's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
OKYO Pharma Quarterly Liabilities And Stockholders Equity |
|
About 28.0% of OKYO Pharma Ltd are currently held by insiders. Unlike OKYO Pharma's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against OKYO Pharma's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of OKYO Pharma's insider trades
OKYO Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as OKYO Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading OKYO Pharma Ltd backward and forwards among themselves. OKYO Pharma's institutional investor refers to the entity that pools money to purchase OKYO Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Barclays Plc | 2024-06-30 | 961 K | Citadel Advisors Llc | 2024-09-30 | 14.9 K | Hpm Partners Llc | 2024-06-30 | 12.8 K | Geode Capital Management, Llc | 2024-09-30 | 12.1 K | Hsbc Holdings Plc | 2024-06-30 | 11.9 K | Susquehanna International Group, Llp | 2024-06-30 | 11.1 K | Ubs Group Ag | 2024-06-30 | 1.9 K | Continuum Advisory, Llc | 2024-06-30 | 50.0 |
OKYO Pharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific OKYO Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on OKYO Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases OKYO Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Denoyer Bernard over six months ago Disposition of 1000000 shares by Denoyer Bernard of OKYO Pharma at 0.1045 subject to Rule 16b-3 | ||
Cerrone Gabriele M over a year ago Acquisition or disposition of OKYO Pharma securities by Cerrone Gabriele M | ||
Brancaccio John P over a year ago Purchase by Brancaccio John P of 16670 shares of OKYO Pharma |
OKYO Pharma Outstanding Bonds
OKYO Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. OKYO Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most OKYO bonds can be classified according to their maturity, which is the date when OKYO Pharma Ltd has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Pair Trading with OKYO Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if OKYO Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OKYO Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against OKYO Stock
The ability to find closely correlated positions to OKYO Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace OKYO Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back OKYO Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling OKYO Pharma Ltd to buy it.
The correlation of OKYO Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as OKYO Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if OKYO Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for OKYO Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OKYO Pharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OKYO Pharma. If investors know OKYO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OKYO Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.57) | Return On Assets (2.92) | Return On Equity (29.69) |
The market value of OKYO Pharma is measured differently than its book value, which is the value of OKYO that is recorded on the company's balance sheet. Investors also form their own opinion of OKYO Pharma's value that differs from its market value or its book value, called intrinsic value, which is OKYO Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OKYO Pharma's market value can be influenced by many factors that don't directly affect OKYO Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OKYO Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if OKYO Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OKYO Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.